Mirum names Rob Myers as CMO, succeeding Joanne Quan
Mirum Pharmaceuticals disclosed a Chief Medical Officer transition, with Myers' start and Quan's separation both described as expected rather than final.
Mirum Pharmaceuticals said its Board of Directors acted on September 2, 2026 to appoint Rob Myers, M.D. as Chief Medical Officer, succeeding Joanne Quan, M.D., according to an 8-K filed September 8, 2026. The appointment is effective upon Dr. Myers' beginning employment with the Company, which employment is expected to begin on September 21, 2026.1
Dr. Quan ceased to serve as the Company's Chief Medical Officer effective September 2, 2026, and her termination of employment with the Company is expected to occur on October 19, 2026, which the filing refers to as the Separation Date.1
In connection with her departure, the Company and Dr. Quan expect to enter into a Separation Agreement under which the Company expects Dr. Quan to be entitled to severance benefits set forth in the Company's Amended and Restated Severance Benefit Plan, subject to that plan's terms and conditions.1 Additionally, the Compensation Committee approved extending the post-termination exercise period for Dr. Quan's vested and outstanding stock options to 12 months after the Separation Date, and approved payment on the Separation Date of her 2026 annual target bonus at the 100% achievement level.1 These additional benefits are contingent on Dr. Quan satisfying certain customary conditions to be set forth in the final Separation Agreement.1 Her separation is expected to qualify as an involuntary termination under the Severance Plan.1
The company said the final Separation Agreement will be filed with its Form 10-Q for the quarter ending September 30, 2026, or its Form 10-K for the year ending December 31, 2026, depending on the agreement's effective date.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.